Nakanishi R, Kume T, Mitsudomi T, Yoshimatsu T, Osaki T, Tokunaga H, Yasumoto K
Second Department of Surgery, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan.
Am J Clin Oncol. 1997 Feb;20(1):31-5. doi: 10.1097/00000421-199702000-00007.
Combining cisplatin and carboplatin may eliminate some of the toxic effects of each agent and permit the use of higher doses, because these agents have different pharmacodynamics and dose-limiting toxicities. We investigated the safety and efficacy of these agents in combination. The toxicity profile was evaluated in a Phase I trial in 18 patients with advanced non-small cell lung cancer (NSCLC). Carboplatin was administered in doses ranging from 200 to 400 mg/m2 on day 1 and cisplatin at a dose of 80 mg/m2 on day 3. Only one cycle of chemotherapy was administered. Thrombocytopenia was the dose-limiting toxic effect. The maximal tolerated dose of carboplatin was 350 mg/m2. We then investigated the efficacy of the optimal dose of this combined chemotherapy in a Phase II trial in 13 patients. We used a carboplatin dose of 300 mg/m2 for safety in the Phase II trial. Three of 13 patients developed grade 3-4 hematologic toxicity, which was improved without major complications. A partial response was observed in 5 of 13 patients (38.5%). Combination chemotherapy with carboplatin (day 1, 300 mg/m2) and cisplatin (day 3, 80 mg/m2) showed promising effects in patients with advanced NSCLC.
顺铂和卡铂联合使用可能会消除每种药物的一些毒性作用，并允许使用更高剂量，因为这些药物具有不同的药效学和剂量限制性毒性。我们研究了这些药物联合使用的安全性和有效性。在一项针对18例晚期非小细胞肺癌（NSCLC）患者的I期试验中评估了毒性特征。卡铂在第1天的给药剂量为200至400mg/m²，顺铂在第3天的给药剂量为80mg/m²。仅进行了一个化疗周期。血小板减少是剂量限制性毒性作用。卡铂的最大耐受剂量为350mg/m²。然后我们在一项针对13例患者的II期试验中研究了这种联合化疗最佳剂量的疗效。在II期试验中，为了安全起见，我们使用卡铂剂量为300mg/m²。13例患者中有3例出现3-4级血液学毒性，经改善后无重大并发症。13例患者中有5例（38.5%）观察到部分缓解。卡铂（第1天，300mg/m²）和顺铂（第3天，80mg/m²）联合化疗在晚期NSCLC患者中显示出有前景的效果。
